Adjuvant Nivolumab Slows Muscle-Invasive Urothelial Carcinoma
Disease-free survival was longer with adjuvant nivolumab in intention-to-treat population, for those with PD-L1 expression at least 1 percent
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.